Tagged with M

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

Denmark Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is guiding the century-old company through a bold transformation, restoring profitability, embracing external innovation, and laying the groundwork for a potential…

Denmark Marianne Pilgaard discusses the evolution of Denmark’s clinical trial landscape, the continued top-tier status of the country in trial activity per capita, and the nation’s commitment to digital innovation and patient-centric research. Pilgaard covers the impact of healthcare reform, regulatory harmonisation, decentralised trials, and the prospects for advanced therapies and…

Switzerland Antoine Geissbühler wears many hats—physician, academic, innovator, and institutional leader—and is at the forefront of digital transformation in healthcare. In this wide-ranging conversation, the Dean of the Faculty of Medicine at the University of Geneva and President of the BioAlps Association shares his journey, insights into Geneva’s unique life sciences…

LatAm MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe 2025. Latin America is at a pivotal moment in the evolution of its regulatory systems. Factors such as the adoption…

Denmark Jakob Nielsen, CEO of Healthcare Denmark, discusses how Denmark has strengthened its role in global health diplomacy and life sciences since 2021. Nielsen highlights the country’s focus on strategic international partnerships, digitalisation, and patient-centric healthcare reform, positioning Denmark as a transparent and collaborative partner in addressing shared healthcare challenges. What…

Denmark Already one of Europe’s top countries for clinical trials per capita, Denmark has further strengthened its position in recent years. The number of active trials in the country rose from 410 in 2022 to 450 in 2023, backed by increasing citizen participation and a healthcare ecosystem built on trusted health…

Puerto Rico Already a solid hub for biopharma manufacturing and logistics, Puerto Rico is moving to sharpen its position in the evolving US reshoring landscape and attract new investment. Under the banner “Made in Puerto Rico is Made in the USA,” Governor Jenniffer Gonzalez-Colon is promoting the island’s unique value as both…

Germany Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and China is at the heart of its strategy. Using vaccine proceeds to tap China’s booming life sciences ecosystem, BioNTech has…

Canada Dr David Reddy, Director General, IFPMA, and Dr Bettina Hamelin, President, IMC, jointly advocate for health innovation at the 2025 G7 Summit in Kananaskis (15-17 June). They call G7 leaders to place health and life-sciences innovation at the heart of the G7 agenda, emphasizing three areas of focus where the…

Puerto Rico Felix and Manuel de la Cruz of M&N Electronics discuss the company’s evolution over the years and its commitment to becoming the leading provider of industrial equipment in Puerto Rico. They highlight the company’s focus on customer service, growth opportunities in the local pharmaceutical sector, and expansion into new markets,…

Denmark Peter Jorgensen, Director of the Danish Generic and Biosimilar Medicines Industry Association, discusses Denmark’s robust framework for generics and biosimilars, offering insight into a system that has delivered high penetration, cost savings, and broad public trust. From legal structures and patient attitudes to incentives and hospital adoption, Jorgensen outlines why…